Overview

Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade

Status:
Not yet recruiting

Trial end date:
2031-10-01

Target enrollment:

Participant gender:

Summary

This study aims to identify HER2-positive early-stage breast cancer patients who could benefit from neoadjuvant treatment using PHESGO™ (pertuzumab and trastuzumab) without chemotherapy. The approach involves utilizing specific biomarkers (HR and HER2 IHC status) to select participants whose tumors strongly rely on the HER2 pathway, potentially benefiting from a HER2-targeted approach without chemotherapy concurrently.

Phase:

Phase 2

Details

Lead Sponsor:

Latin American Cooperative Oncology Group

Collaborators:

Oncoclínicas
Roche Pharma AG